So I saw this on the Research America blog and I thought it worth posting.
The Health Affairs article referred too can be found here. It is unsurprising but nonetheless disappointing that the article does not go into detail about the reasons for the slower adoption in Europe. There will be some geographic-specific and also good regulatory reasons for some of the instances covered but it is worrying that US patients are gettign access to such medicines a long time before EU patients.
The article is another piece of evidence behind the general argument that medical research charities have ben making that the ‘innovation pipeline’ including drug approval needs speeding up in the UK and the rest of Europe. And it is not just about the disincentivisation of research, most important of all it is about patients losing out.